Stream Bio Launches Nano Bioimaging Probes in Italy

Published on: 

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-04-03-2019, Volume 14, Issue 4

Stream Bio entered into a new agreement with DBA Italia to launch Stream Bio’s nanotech-based bioimaging probes in Italy.

On March 12, 2019, Stream Bio, a developer and manufacturer of innovative bioimaging molecular probes, entered into a new agreement with DBA Italia, a supplier of research reagents for immunology, biochemistry, cellular, and molecular biology, to launch Stream Bio’s nanotech-based bioimaging probes in Italy.

The agreement expands Stream Bio’s European distribution network for its Conjugated Polymer Nanoparticles (CPNs), which represent a new generation of novel molecular bioimaging probes. These nanoparticles are highly fluorescent and non-toxic, offering stability, magnetic capability, and suitability to be conjugated with a wide range of molecules.

The launch highlights the continued growth and commercial potential of the CPNs. Stream Bio also recently received an Innovate UK-funded manufacturing and materials loan, which will enable the further expansion of its product range.


The CPNs come in four emission wavelengths ranging from 475–680 nm and can now be streptavidin-linked. Applications for these probes include diagnostics and therapeutics and the potential to be used for imaging tumors and fluorescence-guided surgery. They are already distributed in the United Kingdom and Ireland through 2BScientific, in France through CliniSciences, and in Germany through Biotrend.

Source: Stream Bio